SecBot SecBot
6-K ·Filed May 14, 2026

CMMB

Chemomab Therapeutics Ltd.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago SEC0001178913-26-002672
Notable filing: 6-K
Actionable Insight • Neutral

The cash runway through Q1 2027 provides limited visibility for a pre-revenue biotech. The upcoming EASL presentations on May 30, 2026 and any partnering announcements are the key near-term catalysts. Monitor for partnership deal terms that could extend runway and validate the PSC/IBD thesis.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.70
T+0 close · May 14, 2026 · via day close
Latest settled
+11.18%
T+60 · $1.89
Vs SPY
+7.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $1.70entry
  2. T+1 · 6mo ago −2.35%α −1.13% · $1.66
  3. T+5 · 6mo ago +7.06%α +7.78% · $1.82
  4. T+20 · 5mo ago −2.94%α −2.08% · $1.65
  5. T+60 · 3mo ago +11.18%α +7.59% · $1.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Chemomab Therapeutics reported Q1 2026 financial results, with net loss narrowing to $1.8M from $3.3M YoY on lower R&D spend as the Phase 2 SPRING trial winds down. Cash of $8.0M funds operations through Q1 2027. The company highlighted new biomarker data from nebokitug in PSC suggesting potential benefit in PSC patients with co-existing IBD, and continues to advance partnering discussions.

Key Facts

  • Net loss of $1.8M in Q1 2026 vs $3.3M in Q1 2025
  • Cash, cash equivalents and short-term bank deposits of $8.0M as of March 31, 2026
  • Cash runway expected to fund operations through end of Q1 2027
  • R&D expenses decreased to $0.9M from $2.5M YoY due to winding down of Phase 2 SPRING trial
  • 576,030,200 ordinary shares outstanding as of March 31, 2026 (7,200,377 ADSs)
  • New biomarker data from SPRING trial presented at DDW 2026 and upcoming EASL 2026 shows nebokitug modulates pathways relevant to both PSC and IBD
  • Company continues to advance multiple partnering options for nebokitug

Financial Impact

Net loss improved by $1.5M YoY to $1.8M; cash burn of $2.4M in Q1 2026

net losscash positionR&D expenses

Risk Factors

  • Cash runway only through Q1 2027, financing risk if partnering discussions fail to materialize
  • No revenue and pre-commercial stage, binary risk on Phase 3 trial outcomes
  • Biomarker data is correlative, not proof of clinical efficacy in IBD co-morbidity
  • Small market cap ($13M) amplifies volatility on any news

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001178913-26-002672
Document: zk2635329.htm0001178913-26-002672
Document: 0001178913-26-002672-index-headers.html0001178913-26-002672
Document: 0001178913-26-002672-index.html0001178913-26-002672
Document: 0001178913-26-002672.txt0001178913-26-002672

US Market Status

Market Closed · Opens in 9h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026